Ceapro Inc.

Equities

CZO

CA1499071076

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 10:37:46 31/05/2024 pm IST			5-day change	1st Jan Change
0.225 ^CAD	-11.76%		-16.67%	+18.42%

29/05	Ceapro's Q1 Net Loss Swells YoY, But Talks Up Benefits of Planned Aeterna Merger	MT
29/05	Ceapro Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Ceapro Inc. Appoints Ronnie Miller as Chairman of the Board and Genevieve Foster Will Chair the Audit Committee

June 07, 2022 at 05:35 pm IST

Ceapro Inc. announced that at its Annual General and Special Meeting of Shareholders held on June 1, 2022, Mr. Ronnie Miller will serve as Chairman of the Board and Ms. Genevieve Foster will chair the Audit Committee for the upcoming year.

Latest news about Ceapro Inc.

Ceapro's Q1 Net Loss Swells YoY, But Talks Up Benefits of Planned Aeterna Merger	29/05	MT
Ceapro Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	29/05	CI
Aeterna Zentaris Finalizes Some Details for Ceapro Merger	17/05	MT
Aeterna and Ceapro Brief: Aeterna Zentaris Announcing Details Regarding Transaction with Ceapro	17/05	MT
Ceapro Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/04	CI
Ceapro Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/04	CI
Ceapro Brief: Parties anticipate completing Transaction in Q2 2024, subject to obtaining all required approvals and satisfying all required conditions	28/03	MT
Ceapro Brief: Says Received Final Court Approval for Merger with Aeterna Zentaris	28/03	MT
Aeterna Zentaris Reports Q4 Net Loss of US$5.6 Million, Provides DETECT Trial Update	27/03	MT
Aeterna Zentaris Brief: Announcing Completion of Enrollment in Ongoing Pivotal DETECT-Trial for Diagnosis of Childhood-Onset Growth Hormone Deficiency	27/03	MT
Aeterna Zentaris Brief: Reporting Q4 Net Loss of US$5.6 million, or $1.16 loss per common share	27/03	MT
Ceapro Brief: Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR Arrangement Agreement to Approve Merger of Equals to Create a Diversified Biopharmaceutical Co	26/02	MT
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create Diversified Biopharmaceutical Co	14/12	MT
Aeterna Zentaris and Ceapro Brief: Cos Announcing Merger of Equals to Create a Diversified Biopharmaceutical Co	14/12	MT
Ceapro Inc. Announces Dosing of First Patients In Phase 1-2a Study of Avenanthramides	13/12	MT
Ceapro Inc. Announces Commencement of Patient Dosing in its Phase 1-2a Study Evaluating its Product, Avenanthramides, for Potential Applications in Managing Conditions Related to Inflammation	13/12	CI
Ceapro Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	29/11	CI
Ceapro Inc. Initiates Phase 1-2a Study Assessing Avenanthramides For Potential Applications in Inflammation Based Diseases	28/11	MT
Ceapro Inc. Initiates Phase 1-2A Study Assessing Its Product Avenanthramides for Potential Applications in Inflammation Based Diseases	27/11	CI
Ceapro Inc. entered into a definitive agreement to acquire Aeterna Zentaris Inc. for CAD 0.13 million in a merger of equals transaction.	09/11	CI
Ceapro Inc. Announces the Signing of A Technical Collaboration with NATEX Prozesstechnologie Gmbh to Accelerate the Scale-Up of Its Proprietary PGX Technology Towards Commercial Level	07/11	CI
Ceapro Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	29/23/29	CI
Ceapro Extends International Supply and Distribution Agreement with German Provider of Active Ingredients, Symrise	25/23/25	MT
Ceapro Inc. Extends Exclusive International Supply and Distribution Agreement with Symrise	25/23/25	CI
Ceapro Announces Next Phase of Research Collaboration with the Angiogenesis Foundation	18/23/18	MT

Chart Ceapro Inc.

Duration

Period

More charts

Company Profile

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.

Sector

Biotechnology & Medical Research

Calendar

22/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CEAPRO INC.	+18.42%	14.61M
MODERNA, INC.	+43.36%	58.06B
IQVIA HOLDINGS INC.	-5.31%	40.53B
LONZA GROUP AG	+37.52%	38.99B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.7B
CELLTRION, INC.	-12.56%	26.56B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.98B
BIO-TECHNE CORPORATION	+0.04%	12.17B
UNITED THERAPEUTICS CORPORATION	+25.12%	12B
MEDPACE HOLDINGS, INC.	+26.04%	11.92B

Other Biotechnology & Medical Research